Related Experiment Video

Updated: May 11, 2026

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Propranolol-resistant infantile haemangiomas

S Caussé1, H Aubert, M Saint-Jean

  • 1Department of Dermatology, Centre Hospitalier Universitaire Hôtel-Dieu, 1 place Alexis-Ricordeau, 44093 Nantes Cedex 1, France.

The British Journal of Dermatology
|May 11, 2013
PubMed

Insights

Propranolol-resistant infantile haemangiomas (PRIH) are rare, affecting less than 1% of patients. This study characterizes PRIH, noting its occurrence across various ages and proliferation stages.

Area of Science:

  • Pediatric Dermatology
  • Pharmacology
  • Clinical Research

Background:

  • Propranolol is a standard treatment for severe infantile haemangiomas (IHs).
  • Propranolol-resistant infantile haemangiomas (PRIH) are infrequently documented in medical literature.

Purpose of the Study:

  • To characterize the clinical features of infantile haemangiomas resistant to propranolol treatment.
  • To investigate the prevalence and presentation of PRIH.

Main Methods:

  • A national, multicentre, retrospective, observational study was conducted.
  • Data were collected from patients evaluated between January 2007 and December 2011.

Main Results:

  • Out of 1130 patients treated with propranolol for IH, 10 (0.9%) exhibited PRIH.
  • PRIH was observed in children of all ages and at any stage of haemangioma proliferation.

Conclusions:

  • Propranolol-resistant infantile haemangioma is a rare clinical entity.
  • Further research is warranted to understand the mechanisms and management of PRIH.
Abstract

More Related Videos

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats07:56

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats

Published on: April 21, 2017

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...